Remove 2018 Remove Clinical Trials Remove DEA
article thumbnail

Legislation To Produce And Research Cannabis Introduced

NORML

A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. A similar version of this bill was passed in the House Judiciary Committee in 2018 yet was not taken up by the full chamber.

article thumbnail

The Ketamine Clinic Craze: Legalities and Possibilities

Canna Law Blog

In recent years, the United States has seen a proliferation of ketamine clinics. From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs.

Therapy 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

U.S. Funding Focuses on Marijuana’s Harms, Not Benefits

CannaMD

In Canada, recreational marijuana use was legalized in October 2018. Drug Enforcement Agency (DEA) announced that it will evaluate 37 additional grower applications. One such rule requires that all growers turn over all marijuana and by-products to the DEA shortly after harvest. The DEA would then be the exclusive distributor.

DEA 105
article thumbnail

Cannabis and International Trade: Never the Twain Shall Meet?

Canna Law Blog

2018 was a historic year for the cannabis industry not just in the United States, but also internationally. In September 2018, however, the U.S. Drug Enforcement Administration (DEA) granted permission for a Canadian marijuana company (Tilray) to export medicinal cannabis to University of California San Diego for clinical trial.

article thumbnail

CBD: Everything You Need to Know

CannaMD

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. More recently, the 2018 Farm Bill expanded hemp legislation.

CBD 105
article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Beginning in 2018, the FDA has started to grant special designations to study the medicinal use of psilocybin via Breakthrough Therapy status. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.

Law 81
article thumbnail

Approval of Epidiolex Validates What Many CBD Users Already Knew

MedicalJane

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. Clinical trials show that Epidiolex significantly reduces seizure frequency.